A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs
- PMID: 22149096
- PMCID: PMC3358355
- DOI: 10.1021/mp200392g
A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs
Abstract
Sublingual (SL) delivery, a noninvasive immunization method that bypasses the intestinal tract for direct entry into the circulation, was evaluated with an adenovirus (Ad5)-based vaccine for Ebola. Mice and guinea pigs were immunized via the intramuscular (IM), nasal (IN), oral (PO) and SL routes. SL immunization elicited strong transgene expression in and attracted CD11c(+) antigen presenting cells to the mucosa. A SL dose of 1 × 10⁸ infectious particles induced Ebola Zaire glycoprotein (ZGP)-specific IFN-γ⁺ T cells in spleen, bronchoalveolar lavage, mesenteric lymph nodes and submandibular lymph nodes (SMLN) of naive mice in a manner similar to the same dose given IN. Ex vivo CFSE and in vivo cytotoxic T lymphocyte (CTL) assays confirmed that SL immunization elicits a notable population of effector memory CD8+ T cells and strong CTL responses in spleen and SMLN. SL immunization induced significant ZGP-specific Th1 and Th2 type responses unaffected by pre-existing immunity (PEI) that protected mice and guinea pigs from lethal challenge. SL delivery protected more mice with PEI to Ad5 than IM injection. SL immunization also reduced systemic anti-Ad5 T and B cell responses in naive mice and those with PEI, suggesting that secondary immunizations could be highly effective for both populations.
Figures







Similar articles
-
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.PLoS One. 2008;3(10):e3548. doi: 10.1371/journal.pone.0003548. Epub 2008 Oct 29. PLoS One. 2008. PMID: 18958172 Free PMC article.
-
Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.Mol Pharm. 2013 Sep 3;10(9):3342-55. doi: 10.1021/mp4001316. Epub 2013 Aug 19. Mol Pharm. 2013. PMID: 23915419 Free PMC article.
-
Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.J Infect Dis. 2011 Nov;204 Suppl 3:S1032-42. doi: 10.1093/infdis/jir332. J Infect Dis. 2011. PMID: 21987739
-
Correlates of vaccine-induced protective immunity against Ebola virus disease.Semin Immunol. 2018 Oct;39:65-72. doi: 10.1016/j.smim.2018.07.003. Epub 2018 Jul 21. Semin Immunol. 2018. PMID: 30041831 Review.
-
Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.Curr Opin Immunol. 2015 Aug;35:131-6. doi: 10.1016/j.coi.2015.06.006. Epub 2015 Aug 3. Curr Opin Immunol. 2015. PMID: 26247875 Review.
Cited by
-
Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.Mol Pharm. 2015 Aug 3;12(8):2697-711. doi: 10.1021/mp5006454. Epub 2015 Jan 20. Mol Pharm. 2015. PMID: 25549696 Free PMC article.
-
Current ebola vaccines.Expert Opin Biol Ther. 2012 Jul;12(7):859-72. doi: 10.1517/14712598.2012.685152. Epub 2012 May 5. Expert Opin Biol Ther. 2012. PMID: 22559078 Free PMC article. Review.
-
Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf).PLoS One. 2014 Apr 15;9(4):e94269. doi: 10.1371/journal.pone.0094269. eCollection 2014. PLoS One. 2014. PMID: 24736750 Free PMC article.
-
Buccal and sublingual vaccine delivery.J Control Release. 2014 Sep 28;190:580-92. doi: 10.1016/j.jconrel.2014.05.060. Epub 2014 Jun 6. J Control Release. 2014. PMID: 24911355 Free PMC article. Review.
-
Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.Viruses. 2014 Jul 9;6(7):2673-97. doi: 10.3390/v6072673. Viruses. 2014. PMID: 25010768 Free PMC article.
References
-
- Richardson JS, Dekker JD, Croyle MA, Kobinger GP. Recent Advances in Ebolavirus Vaccine Development. Hum. Vaccine. 2010;6(6):439–449. - PubMed
-
- Towner JS, Sealy TK, Khristova ML, Albariño CG, Conlan S, Reeder SA, Quan PL, Lipkin WI, Downing R, Tappero JW, Okware S, Lutwama J, Bakamutumaho B, Kayiwa J, Comer JA, Rollin PE, Ksiazek TG, Nichol ST. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 2008;4(11):e1000212. - PMC - PubMed
-
- Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. J. Infect. Dis. 1999;179(Suppl. 1):S48–S53. - PubMed
-
- Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST, Rollin PE, Towner JS, Shieh WJ, Batten B, Sealy TK, Carrillo C, Moran KE, Bracht AJ, Mayr GA, Sirios-Cruz M, Catbagan DP, Lautner EA, Ksiazek TG, White WR, McIntosh MT. Discovery of swine as a host for the Reston ebolavirus. Science. 2009;325(5397):204–206. - PubMed
-
- Hartman AL, Towner JS, Nichol ST. Ebola and Marburg Hemorrhagic Fever. Clin. Lab. Med. 2010;30(1):161–177. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials